Terminated OBSERVATIONAL NCT04976231

MPS II Immunophenotyping

Immunophenotyping of Patients With MPS II Treated With Enzyme Replacement Therapy

Sponsor: Duke University

Conditions Hunter Syndrome MPS II Mucopolysaccharidosis II

Updated 13 times since 2021 Last updated: Sep 10, 2024 Started: Apr 1, 2022 Primary completion: Apr 26, 2024 Completion: Apr 26, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low Enrollment

Other terminated trials from Duke University

See all terminations from Duke University

Listed as NCT04976231, this observational or N/A phase trial focuses on Hunter Syndrome and MPS II and remains terminated or withdrawn. Sponsored by Duke University, it has been updated 13 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

13 versions recorded

Oct 2024 — Present [monthly]

Terminated

Status: Recruiting → Terminated
Sep 2024 — Oct 2024 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
May 2024 — Jul 2024 [monthly]

Recruiting
Dec 2023 — May 2024 [monthly]

Recruiting

▶ Show 8 earlier versions

May 2023 — Dec 2023 [monthly]

Recruiting
Jul 2022 — May 2023 [monthly]

Recruiting
Jun 2022 — Jul 2022 [monthly]

Recruiting
May 2022 — Jun 2022 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
Feb 2022 — May 2022 [monthly]

Not Yet Recruiting
Dec 2021 — Feb 2022 [monthly]

Not Yet Recruiting
Nov 2021 — Dec 2021 [monthly]

Not Yet Recruiting
Sep 2021 — Nov 2021 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Duke University

Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Durham, United States